[go: up one dir, main page]

AR066914A1 - Productos extruidos con enmascaramiento del sabor mejorado - Google Patents

Productos extruidos con enmascaramiento del sabor mejorado

Info

Publication number
AR066914A1
AR066914A1 ARP080102433A ARP080102433A AR066914A1 AR 066914 A1 AR066914 A1 AR 066914A1 AR P080102433 A ARP080102433 A AR P080102433A AR P080102433 A ARP080102433 A AR P080102433A AR 066914 A1 AR066914 A1 AR 066914A1
Authority
AR
Argentina
Prior art keywords
extruded products
improved flavor
flavor mask
extruded
mask
Prior art date
Application number
ARP080102433A
Other languages
English (en)
Original Assignee
Bayer Animal Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39790368&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR066914(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Animal Health Gmbh filed Critical Bayer Animal Health Gmbh
Publication of AR066914A1 publication Critical patent/AR066914A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Seasonings (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Fats And Perfumes (AREA)
  • General Preparation And Processing Of Foods (AREA)

Abstract

Productos extruidos que contienen una o varias sustancia(s) farmacéuticamente efectivas, en donde los productos extruidos presentan un diámetro de hebra de 0,5 mm o inferior, así como el uso de estos productos extruidos para la preparacion de medicamentos. Reivindicacion 4: Producto extruido segun una de las reivindicaciones precedentes, que contiene un éster de glicerol con ácidos grasos C12-24 como soporte lipídico.
ARP080102433A 2007-06-08 2008-06-06 Productos extruidos con enmascaramiento del sabor mejorado AR066914A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102007026550A DE102007026550A1 (de) 2007-06-08 2007-06-08 Extrudate mit verbesserter Geschmacksmaskierung

Publications (1)

Publication Number Publication Date
AR066914A1 true AR066914A1 (es) 2009-09-23

Family

ID=39790368

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080102433A AR066914A1 (es) 2007-06-08 2008-06-06 Productos extruidos con enmascaramiento del sabor mejorado

Country Status (36)

Country Link
US (1) US20100197571A1 (es)
EP (1) EP2170272B1 (es)
JP (2) JP5775302B2 (es)
KR (2) KR20150110825A (es)
CN (1) CN101677946A (es)
AR (1) AR066914A1 (es)
AU (1) AU2008258887B2 (es)
BR (1) BRPI0812432B8 (es)
CA (1) CA2689486C (es)
CL (1) CL2008001575A1 (es)
CO (1) CO6260054A2 (es)
CR (1) CR11096A (es)
DE (1) DE102007026550A1 (es)
DK (1) DK2170272T3 (es)
DO (1) DOP2009000255A (es)
EC (1) ECSP099716A (es)
ES (1) ES2625138T3 (es)
GT (1) GT200900287A (es)
HR (1) HRP20170747T1 (es)
HU (1) HUE032719T2 (es)
IL (1) IL201708A0 (es)
MX (1) MX2009011999A (es)
MY (1) MY157780A (es)
NI (1) NI200900198A (es)
NZ (1) NZ581670A (es)
PE (1) PE20090761A1 (es)
PL (1) PL2170272T3 (es)
PT (1) PT2170272T (es)
RU (2) RU2009148576A (es)
SI (1) SI2170272T1 (es)
SV (1) SV2009003403A (es)
TW (1) TWI483738B (es)
UA (1) UA97401C2 (es)
UY (1) UY31117A1 (es)
WO (1) WO2008148484A1 (es)
ZA (1) ZA200908647B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2172191A1 (en) * 2008-10-01 2010-04-07 Heinrich-Heine-Universität Düsseldorf Lipid pellets with enhanced taste-masking
NZ593217A (en) * 2008-12-05 2013-05-31 Bayer Ip Gmbh Extrudate having spicular active substances
DE102009012423A1 (de) * 2009-03-10 2010-09-16 Bayer Animal Health Gmbh Zubereitung auf Ölbasis
HU231017B1 (hu) 2012-05-08 2019-11-28 LAVET Gyógyszeripari Kft. Praziquantel tartalmú ízfedett formulációk
CA2910865C (en) 2014-07-15 2016-11-29 Isa Odidi Compositions and methods for reducing overdose
EP3181317A1 (de) * 2015-12-18 2017-06-21 LANXESS Deutschland GmbH Verfahren zur herstellung von feststoffpartikeln
CN108888598A (zh) * 2018-08-01 2018-11-27 江西成必信生物科技有限公司 口服易吸收的布他磷及其制备方法
CN111529499B (zh) * 2020-06-11 2021-09-17 华中农业大学 一种兽用恩诺沙星风味片剂及其制备方法
US20230372249A1 (en) 2020-09-04 2023-11-23 Elanco Us Inc. Palatable formulations

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5746986A (en) 1980-09-02 1982-03-17 Dai Ichi Seiyaku Co Ltd Pyrido(1,2,3-de)(1,4)benzoxazine derivative
US4670444B1 (en) 1980-09-03 1999-02-09 Bayer Ag and-naphthyridine-3-carboxylic acids and antibacte7-amino-1-cyclopropyl-4-oxo-1,4-dihydro-quinoline-rial agents containing these compounds
US4472405A (en) 1982-11-12 1984-09-18 Riker Laboratories, Inc. Antimicrobial 6,7-dihydro-5,8-dimethyl-9 fluoro-1-oxo-1H, 5H-benzo (ij) quinolizine-2-carboxylic acid and derivatives
US4730000A (en) 1984-04-09 1988-03-08 Abbott Laboratories Quinoline antibacterial compounds
AT392789B (de) 1985-01-23 1991-06-10 Toyama Chemical Co Ltd Verfahren zur herstellung von 1-substituierten aryl-1,4-dihydro-4-oxonaphthyridinderivaten
JPS61240963A (ja) * 1985-04-18 1986-10-27 ユニチカ株式会社 創傷被覆保護材
IN166416B (es) 1985-09-18 1990-05-05 Pfizer
JP2579610B2 (ja) * 1990-09-28 1997-02-05 鳥取大学長 生体内充填剤
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
AUPM969994A0 (en) * 1994-11-28 1994-12-22 Virbac S.A. Equine anthelmintic formulations
JP3418274B2 (ja) * 1995-06-05 2003-06-16 日本化薬株式会社 口腔内感触の良好な錠剤
WO1997031001A1 (de) * 1996-02-23 1997-08-28 Bayer Aktiengesellschaft Gegebenenfalls substituierte 8-cyan-1-cyclopropyl-7-(2,8-diazabicyclo-[4.3.0]-nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäuren und ihre derivate
DE19628776A1 (de) 1996-07-17 1998-01-22 Bayer Ag Oral applizierbare Granulate von Hexahydropyrazinderivaten
AU707949C (en) * 1996-07-30 2006-01-19 Merial, Inc. Anthelmintic formulations
FR2753904B1 (fr) 1996-10-01 1998-10-30 Gattefosse Ets Sa Composition pharmaceutique a liberation modifiee de principe actif, comportant une matrice, et procede de fabrication
CA2227314A1 (en) 1997-01-24 1998-07-24 Hoechst Aktiengesellschaft Preparation of concealed taste preparations of antibacterially active quinolone derivatives
US6171615B1 (en) 1998-07-06 2001-01-09 Gattefoss{acute over (e)} Sustained release theophylline formulations, excipient systems and methods of production
BR9912533A (pt) * 1998-07-31 2002-02-13 Otsuka Pharma Co Ltd Composição farmacêutica tendo sabor melhorado
DE19854355A1 (de) 1998-11-25 2000-05-31 Bayer Ag Kristallmodifikation B von 8-Cyan-1-cyclopropyl-7-(1S, 6S-2,8-diazabicyclo-/4.3.O/nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure
US6500463B1 (en) * 1999-10-01 2002-12-31 General Mills, Inc. Encapsulation of sensitive components into a matrix to obtain discrete shelf-stable particles
KR20030017569A (ko) * 2000-06-28 2003-03-03 테바 파마슈티컬 인더스트리즈 리미티드 카르베딜올
US20020122824A1 (en) 2001-01-24 2002-09-05 Francisco Cabrera Solid phase dispersion of quinolone-or naphthyridonecarboxylic acids
US6716448B2 (en) * 2001-10-05 2004-04-06 Rubicon Scientific Llc Domesticated household pet food including maintenance amounts of ivermectin
CA2462251C (en) 2001-10-05 2011-09-20 Rubicon Scientific, Llc Animal feeds including actives and methods of using same
DE10208344A1 (de) * 2002-02-27 2003-09-04 Roehm Gmbh Schmelzextrusion von Wirkstoffsalzen
US20030190343A1 (en) * 2002-03-05 2003-10-09 Pfizer Inc. Palatable pharmaceutical compositions for companion animals
JP2004099442A (ja) * 2002-09-04 2004-04-02 Nisshin Pharma Inc 難溶性薬物含有製剤およびその製造方法
US20040062778A1 (en) * 2002-09-26 2004-04-01 Adi Shefer Surface dissolution and/or bulk erosion controlled release compositions and devices
RU2005122008A (ru) * 2002-12-13 2006-02-10 Цилаг Аг (Ch) Препараты с контролируемым высвобождением, содержащие трамадол и топирамат
DE10304403A1 (de) 2003-01-28 2004-08-05 Röhm GmbH & Co. KG Verfahren zur Herstellung einer oralen Arzneiform mit unmittelbarem Zerfall und Wirkstofffreisetzung
MY135852A (en) * 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
US20050163842A1 (en) * 2003-12-31 2005-07-28 Garth Boehm Rosiglitazone and metformin formulations
JP4210615B2 (ja) * 2004-03-26 2009-01-21 エスエス製薬株式会社 不快な味がマスキングされた製剤
DE102004015981A1 (de) * 2004-04-01 2005-10-20 Bayer Healthcare Ag Neue kirstalline Form von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure
MXPA06011765A (es) 2004-04-12 2006-12-15 Pfizer Prod Inc Farmacos de sabor enmascarado en multiparticulados que se rompen.
GB2418854B (en) * 2004-08-31 2009-12-23 Euro Celtique Sa Multiparticulates
JP4731941B2 (ja) * 2005-02-14 2011-07-27 大正薬品工業株式会社 経口製剤用粒子
WO2007063552A1 (en) * 2005-12-02 2007-06-07 Lupin Limited Stable taste masked formulations of cephalosporins

Also Published As

Publication number Publication date
WO2008148484A1 (de) 2008-12-11
PT2170272T (pt) 2017-05-24
BRPI0812432B8 (pt) 2021-05-25
ZA200908647B (en) 2011-02-23
UY31117A1 (es) 2009-01-30
NI200900198A (es) 2011-12-14
AU2008258887A1 (en) 2008-12-11
CA2689486C (en) 2016-03-22
BRPI0812432A2 (pt) 2014-12-02
US20100197571A1 (en) 2010-08-05
DE102007026550A1 (de) 2008-12-11
JP5775302B2 (ja) 2015-09-09
DK2170272T3 (en) 2017-06-06
TWI483738B (zh) 2015-05-11
HRP20170747T1 (hr) 2017-07-28
BRPI0812432B1 (pt) 2019-04-16
CR11096A (es) 2010-06-28
AU2008258887B2 (en) 2014-06-26
PE20090761A1 (es) 2009-07-23
RU2014124814A (ru) 2015-12-27
NZ581670A (en) 2012-07-27
EP2170272A1 (de) 2010-04-07
TW200914051A (en) 2009-04-01
EP2170272B1 (de) 2017-03-29
UA97401C2 (ru) 2012-02-10
ECSP099716A (es) 2009-12-28
MX2009011999A (es) 2009-11-19
ES2625138T3 (es) 2017-07-18
CN101677946A (zh) 2010-03-24
KR20150110825A (ko) 2015-10-02
RU2009148576A (ru) 2011-07-20
CA2689486A1 (en) 2008-12-11
JP2010529059A (ja) 2010-08-26
CO6260054A2 (es) 2011-03-22
GT200900287A (es) 2011-11-09
HUE032719T2 (en) 2017-10-30
IL201708A0 (en) 2010-05-31
SV2009003403A (es) 2010-05-17
MY157780A (en) 2016-07-29
KR20100017385A (ko) 2010-02-16
DOP2009000255A (es) 2009-12-15
KR101600800B1 (ko) 2016-03-08
PL2170272T3 (pl) 2017-08-31
CL2008001575A1 (es) 2008-12-19
JP2014114310A (ja) 2014-06-26
SI2170272T1 (sl) 2017-06-30

Similar Documents

Publication Publication Date Title
AR066914A1 (es) Productos extruidos con enmascaramiento del sabor mejorado
UY30709A1 (es) Nuevos derivados de 1,4-benzotiepina-1, 1-dioxido sustituidos con radicales bencilo, método para su preparacion, productos farmacéuticos que comprenden estos compuestos y su uso.
PA8827901A1 (es) Derivados de quinoxalin- y quinolin-carboxamida
CL2008001180A1 (es) Un polvo bebestible instantaneo que comprende un agente de relleno y/o azucar recubiertas al menos parcialmente con un 0,1-5% de aceite de cadenas cortas de acidos grasos saturados de trigleceridos saturados c4-c14; capsula que comprende el polvo bebestible; metodo de produccion del polvo; kit que comprende un polvo bebestible.
PA8815201A1 (es) Compuestos heterociclicos
MX2010001401A (es) Productos medicos mejorados, revestidos con preparaciones farmaceuticas, la produccion de los mismos y el uso de los mismos.
ECSP088414A (es) Derivados de ácido bifeniloxiacético para el tratamiento de una enfermedad respiratoria
MX386820B (es) Microcápsulas lipídicas que comprenden de preferencia un retinoide y composición que las contiene, su procedimiento de preparación y su uso en dermatología.
CL2007001452A1 (es) Compuestos derivados de 3h-pirido[2,3-d]pirimidin-4-ona, agonistas de hm74a; procedimiento de preparacion; composicion farmaceutica qu ecomprende a dichos compuestos; y uso para tratar enfermedades tales como niveles altos de lipidos, niveles altos de colesterol, hipertrigliceridemia, trombosis, angina de pecho, apoplejia, entre otras.
CR20120414A (es) Derivados de arilmetoxi isoindolina y composiciones que los comprenden y métodos para utilizar los mismos
BR112013003004A2 (pt) processos para a preparação de tubulisinas
CL2008000806A1 (es) Compuestos derivados de aza piridopirimidinona, con actividad agonista de hm74a; procedimiento de preparacion de dichos compuestos; composicion farmaceutico que las comprende; y su uso para preparar medicamentos para el tratamiento de enferemedades ateroscleroticas, dislipidemias, alzheimer, diabetes, entre otras.
ECSP11011348A (es) 2-mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3
CL2012000319A1 (es) Uso de una composición farmaceutica que comprende treprostinil para la preparación de un medicamento para el tratamiento o la prevención de una afección asociada a la fibrosis quística.
UY29223A1 (es) Ácidos fenoxiacéticos sustituidos, composiciones farmacéuticas que los contienen y procesos para su preparación
ECSP11011346A (es) 3-Amino-2-mercaptoquinolina sustituida como modulador de KCNQ2/3
ECSP11011345A (es) 2-mercapto-3-aminopiridina sustituida como moduladores de kcnq2/3
GT201200216A (es) Nuevos derivados terciarios de 8-hidroxiquinolina-7carboxamida y usos de los mismos.
UY29065A1 (es) Derivados del ácido alcanoico arilcicloalquil-sustituidos, procedimientos para su preparación y su uso como productos farmacéuticos.
MX2012000768A (es) Derivados de tazaroteno.
CO6331424A2 (es) Formulacion farmaceutica de eprosartan
CU20120091A7 (es) Nuevos derivados de azabiciclo[3.1.0]hex-2-ilo, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CR20140350A (es) Composiciones enriquecidas con dpa de ácidos grasos omega 3 poliinsaturados en forma de ácido libre
UY32718A (es) Compuestos derivados de 1, 3, 4-tiadiazol, útiles como agonistas del receptor de esfingosina 1-fosfato
DOP2007000135A (es) Nuevos derivados de 1,4-benzotiepina-1,1-dioxido sustituidos con radicales benciclo, metodo para su preparacion, productos farmaceuticos que comprenden estos compuestos y su uso.

Legal Events

Date Code Title Description
FB Suspension of granting procedure